2. Protein Tyrosine Kinase/RTK
  3. IGF-1R
  4. Robatumumab

Robatumumab  (Synonyms: Sch 717454; 19D12)

Cat. No.: HY-P99218

Molarity Calculator

Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.

For research use only. We do not sell to patients.

CAS No. : 934235-44-6

Size Price Stock Quantity
1 mg USD 290 In-stock
5 mg USD 725 In-stock
10 mg USD 1160 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Robatumumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research[1][2].

Isotype

Human IgG1(E356D/M358L) kappa
Recommend Isotype Controls
Species

Human
In Vitro

Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Robatumumab Related Antibodies

Western Blot Analysis[2]

Cell Line: SK-N-FI cells
Concentration: 0.02-80 nM
Incubation Time: 0.5 or 4 hours
Result: Inhibited the IGF-I–stimulated phosphorylation of IGF-IR after treatment 0.5 h.
Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h.
Resulted in a dose-dependent inhibition of the IGF-I–stimulated IRS-1 phosphorylation.
In Vivo

Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model[2].
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2].
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nude mice inoculated with SK-N-FI tumor cells[2]
Dosage: 0.04 or 0.1 mg/mouse
Administration: Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days
Result: Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group.
Animal Model: Nude mice inoculated with SJSA-1 osteosarcoma[2]
Dosage: 0.02, 0.1 or 0.5 mg/mouse
Administration: Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days
Result: Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment.
Animal Model: Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2]
Dosage: 0.1 or 0.5 mg/mouse
Administration: Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days
Result: Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model.
Animal Model: Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2]
Dosage: 0.1 or 0.5 mg/mouse
Administration: Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks
Result: Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft.
Animal Model: Nude mice inoculated with SJSA-1 osteosarcoma[2]
Dosage: 0.5 mg/mouse
Administration: Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation
Result: Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Robatumumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Robatumumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Robatumumab934235-44-6Sch 717454 19D12Sch717454Sch-717454IGF-1RInsulin-like growth factor-1 receptoranti-tumor activityanti-proliferative activityosteosarcomaEwing sarcomaSK-N-FI cellInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Robatumumab
Cat. No.:
HY-P99218
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.